arrow
G

Giulia Piccini

vismederi srl
H指数:15
被引数:1,453

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Safety and immunogenicity of UB-612 heterologous booster in adults primed with mRNA, adenovirus, or inactivated COVID-19 vaccines: a randomized, active-controlled, Phase 3 trial

UB-612异源加强针在已完成mRNA、腺病毒或灭活COVID-19疫苗基础免疫的成年人中的安全性与免疫原性:一项随机、活性对照、III期临床试验

2025-07-210
PRE
Immunogenicity and safety of COVID-19 booster vaccination: A population-based clinical trial to identify the best vaccination strategy

新型冠状病毒肺炎加强疫苗接种的免疫原性和安全性: 一项基于人群的临床试验,以确定最佳的疫苗接种策略

2024-08-012
PRE
Evaluation of monkeypox- and vaccinia-virus neutralizing antibodies before and after smallpox vaccination: A sero-epidemiological study

天花疫苗接种前后猴痘和牛痘病毒中和抗体的评估: 一项血清流行病学研究

2024-06-112
OA
B cell analyses after SARS-CoV-2 mRNA third vaccination reveals a hybrid immunity like antibody response
2023-01-0415
OAAI
The neutralizing response to SARS-CoV-2 Omicron variants BA.1 and BA.2 in COVID-19 patients and homologous and heterologous vaccinees

COVID-19患者以及同源和异源疫苗对SARS-CoV-2 Omicron变体BA.1和BA.2的中和反应

2022-10-212
OAAI
Immune response to SARS-CoV-2 Omicron variant in patients and vaccinees following homologous and heterologous vaccinations
2022-09-0210
OAAI
Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody
2022-05-1223
OAAI
Safety and serum distribution of anti-SARS-CoV-2 monoclonal antibody MAD0004J08 after intramuscular injection
2022-04-2710
OAAI
Hybrid immunity improves B cells and antibodies against SARS-CoV-2 variants
Nature
IF48.5
2021-10-200
OAAI
SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma

SARS-CoV-2从高度中和的新型冠状病毒肺炎恢复期血浆中逸出

2021-08-20213
OAAI